Encephalitis News and Research

Latest Encephalitis News and Research

Research finds 50 million people vaccinated against zoonotic brain infection

Research at the University of Liverpool has supported the vaccination of more than 50 million people against a zoonotic brain infection that affects thousands of children across Asia every year.

7 Oct 2009

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.

6 Oct 2009

MSF calls on drug companies to pool HIV patents

Medecins Sans Frontieres (MSF) recently launched an e-mail campaign calling on nine of the world's largest pharmaceutical companies to "release their patents on specific HIV drugs into a collective pool that will increase access and affordability to treatment in developing countries," Inter Press Service reports (Borde, 10/1).

5 Oct 2009

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

Virginia Tech student granted fellowship for research study on LaCrosse Virus disease

Camille Harris of Ridgeland, Mississippi, a graduate student in biological sciences at Virginia Tech, has been awarded a National Institutes of Health (NIH) Graduate Research Fellowship for her study of forest disturbance and its ecological impacts on LaCrosse Virus, a mosquito-borne disease that can cause seizures, coma, paralysis, and permanent brain damage in severe cases.

26 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Avisio to acquire a portable sensory technology asset to instantly detect disease-causing pathogens

Avisio, Inc. (PINKSHEETS: AVIC), a publicly traded commercialization company providing access to best-of-breed processes and resources, today announced that it has signed a Letter of Intent to acquire a portable sensory technology asset that enables instant detection of infectious diseases, eliminating the need for processing samples in a lab.

26 Aug 2009

USDA donates funds for teaching food safety awareness to AIDS patients

Researchers at the University of Illinois at Chicago School of Public Health have received a grant from the U.S. Department of Agriculture to educate AIDS patients on food safety.

25 Aug 2009

West Nile Virus threat continues in Pennsylvania

Department of Environmental Protection Secretary John Hanger today reminded Pennsylvania's citizens that although the number of West Nile Virus cases has dropped, the threat still exists.

21 Aug 2009

Pennsylvania's first case of West Nile in 2009 confirmed

State Health Secretary Everette James today reported this year's first confirmed human case of West Nile virus in Pennsylvania. The individual is a 21-year-old woman from Luzerne County.

12 Aug 2009

H5N1 avian influenza leaves people at increased risk for Parkinson's disease

At least one strain of the H5N1 avian influenza virus leaves survivors at significantly increased risk for Parkinson's disease and possibly other neurological problems later in life, according to new research from St. Jude Children's Research Hospital.

10 Aug 2009

Drug derived from the hydrangea root shows promise for autoimmune disorders

A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine.

4 Jun 2009

Second death from mosquito-borne disease prompts calls for more spraying programs

The recent death of a second person from Murray Valley Encephalitis (MVE) in Northern Australia has prompted calls for an increase in mosquito control spraying programs.

28 May 2009

Alzheimer's vaccine slows progression of inclusion body myositis

A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly.

13 May 2009

New insights into how brain responds to viral infection

Scientists at Columbia University Mailman School of Public Health have discovered that astrocytes, supportive cells in the brain that are not derived from an immune cell lineage, respond to a molecule that mimics a viral infection using cellular machinery similar to that used by classical immune cells in the blood.

1 Apr 2009

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE).

30 Mar 2009

FDA approves IXIARO for Japanese encephalitis

The U.S. Food and Drug Administration has approved IXIARO, a vaccine to prevent Japanese encephalitis (JE) which is caused by a mosquito-transmitted virus found mainly in Asia. IXIARO will be the only vaccine for JE available in the United States.

30 Mar 2009

Discovery of protein that reactivates latent herpes simplex virus

Research in Public Library of Science (PLoS) Pathogens appears to solve a long standing medical mystery by identifying a viral protein, VP16, as the molecular key that prompts herpes simplex virus (HSV) to exit latency and cause recurrent disease.

29 Mar 2009

Global elimination of rabies appears to be possible

Someone in the developing world - particularly in rural Africa - dies from a rabid dog bite every 10 minutes.

12 Mar 2009

Hendra and Nipah viruses shown to be susceptible to chloroquine

Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology.

5 Mar 2009